Andrzej Boguszewski, MD
Interventional Cardiology · Midland, MINPI 1063580595
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,721 of the $3,766 with a category attached, or 72.3%. 17 manufacturers reported payments, led by Abbott at 53.6% of the total. Reporting peaked in 2023 at $1,822 and has fallen 80.2% since, to $360 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MI, where the typical reported total is $6,857.
Across 79 payments — averaging $47.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boehringer Ingelheim$351
- Abiomed$349
- AstraZeneca$329
- Medtronic$236
- Novartis$114
- plus $369 from 11 others
Across 12 payments — averaging $66,346 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$775K
- AstraZeneca$22K
What the payments were for
- Travel & lodging$1,04528%
- Food & beverage$2,72172%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $2,017 |
| Boehringer Ingelheim | 18 | $351 |
| Abiomed | 6 | $349 |
| AstraZeneca | 12 | $329 |
| Medtronic | 3 | $236 |
| Novartis | 6 | $114 |
| Shockwave Medical, Inc | 1 | $84 |
| E.r. Squibb & Sons, L.L.C. | 4 | $55 |
| Amgen | 3 | $48 |
| Johnson & Johnson | 3 | $41 |
| Edwards Lifesciences | 1 | $39 |
| Livanova USA, Inc. | 1 | $25 |
| Pfizer | 1 | $22 |
| Teleflex LLC | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Lundbeck LLC | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$1,294
- Impella$237
- PORTICO$162
- XIENCE ALPINE$136
- FARXIGA$124
- Optis Coronary Imaging System$114
- OPTIS$113
How this compares
$3,766 in reported general payments places this provider in the 35th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 222 | $306,536 |
| XareltoRivaroxaban | 85 | $123,090 |
| Repatha SureclickEvolocumab | 100 | $87,299 |
| BrilintaTicagrelor | 125 | $71,130 |
| MultaqDronedarone Hcl | 23 | $47,291 |
| JardianceEmpagliflozin | 36 | $39,364 |
| EntrestoSacubitril/Valsartan | 26 | $38,593 |
| Praluent PenAlirocumab | 27 | $24,346 |
| Atorvastatin Calcium | 523 | $7,289 |
| Bisoprolol Fumarate | 204 | $5,599 |
| Metoprolol Succinate | 318 | $4,386 |
| ClopidogrelClopidogrel Bisulfate | 264 | $4,176 |
| Ezetimibe | 112 | $3,017 |
| Ranolazine ErRanolazine | 24 | $2,778 |
| Rosuvastatin Calcium | 151 | $2,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $22 | $306,536222 claims |
| Johnson & JohnsonXarelto | $41 | $123,09085 claims |
| AstraZenecaBrilinta | $329 | $71,130125 claims |
| Sanofi-aventis U.S. LLCMultaq | $19 | $47,29123 claims |
| Boehringer IngelheimJardiance | $351 | $39,36436 claims |
| NovartisEntresto | $114 | $38,59326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Midland
- William FeltenMidland$69K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
- Vishal GuptaKalamazoo$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.